Paolo A Ascierto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6378051/publications.pdf

Version: 2024-02-01

642	72,370	2311 98	750 250
papers	citations	h-index	g-index

671	671	671	51142
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
2	Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
3	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2017, 377, 1345-1356.	13.9	3,589
4	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2019, 381, 1535-1546.	13.9	2,484
5	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353
6	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824
7	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine, 2017, 377, 1824-1835.	13.9	1,752
8	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repairâ€“Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 2020, 38, 1-10.	0.8	1,740
9	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487
10	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	13.9	1,441
11	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	5.1	1,419
12	Towards the introduction of the â€˜Immunoscoreâ€™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
13	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	13.9	1,140
14	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.1	1,093
15	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 883-895.	5.1	1,091
16	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	5.1	890
17	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	5.1	841
18	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	5.1	832

#	Article	IF	Citations
19	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022, 386, 24-34.	13.9	766
20	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 603-615.	5.1	751
21	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 853-861.e4.	7.7	725
22	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
23	The immune score as a new possible approach for the classification of cancer. Journal of Translational Medicine, 2012, 10, 1.	1.8	656
24	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, The, 2013, 14, 249-256.	5.1	587
25	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
26	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
27	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1315-1327.	5.1	469
28	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	3.2	459
29	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 2018, 36, 2836-2844.	0.8	459
30	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
31	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 2017, 81, 116-129.	1.3	443
32	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	5.1	428
33	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 395, 1835-1844.	6.3	423
34	BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. Journal of Clinical Oncology, 2012, 30, 2522-2529.	0.8	419
35	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	5.1	399
36	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 3205-3211.	0.8	395

#	Article	IF	Citations
37	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1884-1901.	0.6	394
38	Adjuvant nivolumab versus ipilimumab in resected stage IIIBâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	5.1	330
39	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Annals of Oncology, 2016, 27, 732-738.	0.6	321
40	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology, 2014, 3, e28780.	2.1	318
41	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
42	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	3.4	295
43	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
44	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research, 2017, 23, 1929-1936.	3.2	290
45	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	3.4	287
46	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
47	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology, The, 2012, 13, 879-886.	5.1	273
48	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research, 2005, 11, 1835-1841.	3.2	260
49	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology, 2019, 37, 867-875.	0.8	258
50	Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies. Seminars in Oncology, 2010, 37, 508-516.	0.8	256
51	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine, 2019, 25, 941-946.	15.2	256
52	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
53	Survival of patients with advanced metastatic melanoma: the impact of novel therapiesâ€“update 2017. European Journal of Cancer, 2017, 83, 247-257.	1.3	236
54	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet, The, 2022, 399, 1718-1729.	6.3	236

#	Article	IF	Citations
55	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nature Communications, 2020, 11, 2168.	5.8	231
56	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	2.0	230
57	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
58	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Annals of Oncology, 2020, 31, 1320-1335.	0.6	219
59	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668.	0.8	218
60	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	15.2	218
61	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European Journal of Cancer, 2017, 86, 334-348.	1.3	212
62	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology, 2017, 28, 2581-2587.	0.6	201
63	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncology, The, 2015, 16, 729-736.	5.1	198
64	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 2020, 38, 3925-3936.	0.8	192
65	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	0.8	190
66	Initial efficacy of anti-lymphocyte activation gene-3 (antiâ€“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiâ€“PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	0.8	188
67	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology, 2019, 37, 1608-1616.	0.8	185
68	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 2017, 86, 37-45.	1.3	183
69	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	5.1	183
70	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. Journal of Thoracic Oncology, 2020, 15, 426-435.	0.5	181
71	Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. Journal of Clinical Oncology, 2010, 28, 2220-2226.	0.8	163
72	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	3.2	161

#	Article	IF	Citations
73	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
74	The influence of diet on anti-cancer immune responsiveness. Journal of Translational Medicine, 2018, 16, 75.	1.8	158
75	Main roads to melanoma. Journal of Translational Medicine, 2009, 7, 86.	1.8	157
76	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
77	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	1.8	149
78	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	1.3	149
79	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	3.2	146
80	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Annals of Oncology, 2018, 29, 2163-2174.	0.6	145
81	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
82	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134.	1.3	137
83	Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clinical Cancer Research, 2013, 19, 1009-1020.	3.2	134
84	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	1.3	132
85	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	0.6	132
86	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	1.9	131
87	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600â€“mutant melanoma. European Journal of Cancer, 2020, 126, 33-44.	1.3	130
88	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
89	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
90	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist, 2016, 21, 1218-1229.	1.9	125

#	Article	IF	Citations
91	Mucosal melanoma of the head and neck. Critical Reviews in Oncology/Hematology, 2017, 112, 136-152.	2.0	125
92	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
93	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 3003-3003.	0.8	120
94	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Annals of Oncology, 2013, 24, 2911-2915.	0.6	119
95	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	0.8	119
96	NF-Î²B as potential target in the treatment of melanoma. Journal of Translational Medicine, 2012, 10, 53.	1.8	118
97	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology, 2015, 26, 798-803.	0.6	118
98	Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Annals of Oncology, 2022, 33, 929-938.	0.6	115
99	Human Melanoma Metastases Express Functional CXCR4. Clinical Cancer Research, 2006, 12, 2427-2433.	3.2	114
100	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of Translational Medicine, 2012, 10, 107.	1.8	112
101	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
102	Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. Journal of Clinical Oncology, 1999, 17, 304-304.	0.8	109
103	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Journal of Translational Medicine, 2013, 11, 54.	1.8	104
104	MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. American Journal of Clinical Dermatology, 2017, 18, 745-754.	3.3	104
105	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	5.1	104
106	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. Journal of Neuro-Oncology, 2014, 118, 109-116.	1.4	103
107	Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior antiâ€“PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology, 2017, 28, v611-v612.	0.6	102
108	miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5005-13.	3.3	99

#	Article	IF	Citations
109	PD-L1 expression as a potential predictive biomarker. Lancet Oncology, The, 2015, 16, 1285-1287.	5.1	98
110	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	1.8	98
111	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	3.5	97
112	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIVÂor hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	1.3	97
113	Effect of nivolumab on health-related quality of life in patients with treatment-naÃ¯ve advanced melanoma: results from the phase III CheckMate 066 study. Annals of Oncology, 2016, 27, 1940-1946.	0.6	94
114	Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of Oncology, 2017, 28, 1137-1144.	0.6	94
115	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1944-1956.	1.3	94
116	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptaseâ€“Polymerase Chain Reaction. Journal of Clinical Oncology, 2003, 21, 767-773.	0.8	91
117	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2017, 18, 393-403.	5.1	91
118	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	0.6	90
119	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600â€“Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1428-1438.	0.8	90
120	Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. European Journal of Surgical Oncology, 2016, 42, 1914-1923.	0.5	89
121	MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 2017, 8, 22262-22278.	0.8	89
122	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3831-3837.	0.8	88
123	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research, 2014, 20, 6258-6268.	3.2	88
124	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88
125	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF^{V600E}-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, 8502-8502.	0.8	86
126	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine, 2017, 15, 46.	1.8	85

#	Article	IF	Citations
127	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	1.3	85
128	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	1.3	84
129	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine, 2013, 11, 145.	1.8	82
130	Anti-IL6R role in treatment of COVID-19-related ARDS. Journal of Translational Medicine, 2020, 18, 165.	1.8	82
131	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutationâ€"Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research, 2021, 27, 5225-5235.	3.2	82
132	Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. Journal of Immunotoxicology, 2012, 9, 241-247.	0.9	81
133	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	1.3	81
134	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Frontiers in Oncology, 2015, 5, 183.	1.3	80
135	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunology, Immunotherapy, 2005, 54, 781-791.	2.0	78
136	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 2020, 26, 1557-1563.	15.2	78
137	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. , 2020, 8, e000930.		77
138	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. OncoImmunology, 2018, 7, e1387706.	2.1	76
139	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	0.6	76
140	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, courseÂand management. European Journal of Cancer, 2019, 119, 97-106.	1.3	75
141	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 552.	2.2	74
142	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine, 2017, 15, 244.	1.8	73
143	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology, 2015, 4, e1008842.	2.1	72
144	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. , 2020, 8, e001089.		72

#	Article	IF	Citations
145	Combination therapy: the next opportunity and challenge of medicine. Journal of Translational Medicine, 2011, 9, 115.	1.8	71
146	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213.	1.6	71
147	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 2018, 91, 116-124.	1.3	69
148	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1794-1806.	0.5	69
149	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1449-1461.	0.6	69
150	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Frontiers in Pharmacology, 2018, 9, 856.	1.6	68
151	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. Expert Opinion on Biological Therapy, 2017, 17, 735-746.	1.4	66
152	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 318.	3.5	66
153	Immunological effects of BRAF+MEK inhibition. OncoImmunology, 2018, 7, e1468955.	2.1	66
154	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600â€“Mutated Metastatic Melanoma. JAMA Oncology, 2018, 4, 1382.	3.4	65
155	Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Annals of Oncology, 2019, 30, v533-v534.	0.6	65
156	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open, 2022, 7, 100404.	2.0	65
157	Adjuvant therapy of melanoma with interferon: lessons of the past decade. Journal of Translational Medicine, 2008, 6, 62.	1.8	64
158	Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. Journal of Translational Medicine, 2011, 9, 196.	1.8	64
159	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	1.3	64
160	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
161	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. Journal of Clinical Oncology, 2001, 19, 1437-1443.	0.8	63
162	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63

#	Article	IF	Citations
163	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Journal of Translational Medicine, 2013, 11, 180.	1.8	61
164	A Serum Protein Signature Associated with Outcome after Antiâ€“PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research, 2018, 6, 79-86.	1.6	61
165	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	1.3	61
166	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunology, Immunotherapy, 2019, 68, 97-107.	2.0	61
167	Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. British Journal of Dermatology, 2000, 142, 893-898.	1.4	60
168	Nivolumab (nivo) Â± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.. Journal of Clinical Oncology, 2017, 35, 8503-8503.	0.8	60
169	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. OncoImmunology, 2017, 6, e1261242.	2.1	59
170	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438.	1.1	59
171	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
172	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. Journal of Translational Medicine, 2013, 11, 135.	1.8	57
173	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. Journal of Clinical Oncology, 2016, 34, 3500-3500.	0.8	57
174	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600â€“mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Annals of Oncology, 2020, 31, S1172.	0.6	56
175	BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. Journal of Clinical Oncology, 2004, 22, 286-292.	0.8	55
176	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, The, 2014, 15, 297-304.	5.1	55
177	Proportions of blood-borne VÎ´1+ and VÎ´2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	1.3	54
178	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open, 2016, 1, e000068.	2.0	54
179	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
180	Melanoma: A model for testing new agents in combination therapies. Journal of Translational Medicine, 2010, 8, 38.	1.8	53

#	Article	IF	Citations
181	Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer, 2013, 13, 564.	1.1	53
182	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	3.2	53
183	Nivolumab Â± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. Journal of Clinical Oncology, 2017, 35, 4014-4014.	0.8	53
184	The use of interferon in melanoma patients: A systematic review. Cytokine and Growth Factor Reviews, 2015, 26, 203-212.	3.2	52
185	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. European Journal of Cancer, 2021, 157, 250-258.	1.3	52
186	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. Journal of Clinical Oncology, 2018, 36, 9502-9502.	0.8	52
187	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. EBioMedicine, 2015, 2, 92-93.	2.7	51
188	KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Annals of Oncology, 2018, 29, viii442.	0.6	51
189	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Research, 2005, 15, 235-244.	0.6	50
190	Serious haematological toxicity during and after ipilimumab treatment: a case series. Journal of Medical Case Reports, 2014, 8, 240.	0.4	50
191	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	5.8	50
192	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. Journal of Clinical Oncology, 2016, 34, 4010-4010.	0.8	50
193	Genetic alterations in main candidate genes during melanoma progression. Oncotarget, 2018, 9, 8531-8541.	0.8	50
194	Systematic review of the use of granulocyteâ€“macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2016, 65, 1015-1034.	2.0	49
195	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget, 2017, 8, 8890-8899.	0.8	48
196	Interleukin 18: Friend or foe in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 296-303.	3.3	47
197	Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Annals of Oncology, 2017, 28, 1672-1673.	0.6	47
198	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. Cancer Immunology Research, 2019, 7, 841-852.	1.6	47

#	Article	IF	Citations
199	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death and Differentiation, 2019, 26, 1267-1282.	5.0	47
200	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer, 2020, 125, 114-120.	1.3	47
201	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs, 2017, 31, 51-61.	2.2	46
202	HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease. Journal of Cellular Physiology, 2017, 232, 3422-3432.	2.0	46
203	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma. JAMA Oncology, 2020, 6, 1957.	3.4	46
204	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
205	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	0.6	45
206	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	1.4	45
207	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. International Journal of Cardiology, 2019, 292, 171-179.	0.8	44
208	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Review of Clinical Pharmacology, 2019, 12, 259-266.	1.3	44
209	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Journal of Translational Medicine, 2014, 12, 216.	1.8	43
210	Electrochemotherapy as â€œnew standard of careâ€•treatment for cutaneous Kaposi's sarcoma. European Journal of Surgical Oncology, 2014, 40, 61-66.	0.5	43
211	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206.	2.1	43
212	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Scientific Reports, 2019, 9, 7449.	1.6	43
213	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer, 2009, 9, 352.	1.1	42
214	Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 564-571.	1.8	42
215	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. Journal of Translational Medicine, 2017, 15, 17.	1.8	40
216	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-Î± 2b treatment. Journal of Translational Medicine, 2010, 8, 76.	1.8	39

#	Article	IF	Citations
217	The role of MEK inhibitors in the treatment of metastatic melanoma. Current Opinion in Oncology, 2014, 26, 196-203.	1.1	39
218	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
219	Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.. Journal of Clinical Oncology, 2015, 33, 9006-9006.	0.8	39
220	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. Journal of Clinical Oncology, 2015, 33, 9007-9007.	0.8	39
221	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. BMC Cancer, 2013, 13, 17.	1.1	38
222	Whatâ€™s new in melanoma? Combination!. Journal of Translational Medicine, 2015, 13, 213.	1.8	38
223	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	3.4	38
224	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 2020, 8, 203.	2.1	38
225	Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. British Journal of Dermatology, 2007, 158, 071119222739015-???.	1.4	37
226	Microenvironment and tumor progression of melanoma: New therapeutic prospectives. Journal of Immunotoxicology, 2013, 10, 235-252.	0.9	37
227	PD-L1 inhibitors in the pipeline: Promise and progress. OncoImmunology, 2018, 7, e1365209.	2.1	37
228	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. Journal of Molecular Diagnostics, 2019, 21, 756-767.	1.2	37
229	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
230	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. European Journal of Cancer, 2021, 155, 268-280.	1.3	37
231	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunology, Immunotherapy, 2007, 56, 1589-1595.	2.0	36
232	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. Journal of Translational Medicine, 2013, 11, 161.	1.8	36
233	Unexpected Distribution of <i>cKIT</i> and <i>BRAF</i> Mutations among Southern Italian Patients with Sinonasal Melanoma. Dermatology, 2013, 226, 279-284.	0.9	36
234	Novel Approaches in Melanoma Prevention and Therapy. Cancer Treatment and Research, 2014, 159, 443-455.	0.2	36

#	Article	IF	Citations
235	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. British Journal of Cancer, 2016, 115, 1280-1284.	2.9	36
236	Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 2017, 15, 146.	1.8	36
237	Checkpoint inhibitors in melanoma and early phase development in solid tumors: whatâ€™s the future?. Journal of Translational Medicine, 2017, 15, 173.	1.8	36
238	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Research, 2003, 13, 167-170.	0.6	35
239	Increased HOX C13 expression in metastatic melanoma progression. Journal of Translational Medicine, 2012, 10, 91.	1.8	35
240	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncology, 2015, 11, 703-712.	1.1	35
241	Antitumor Activity of BRAF Inhibitor and IFNÎ± Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35
242	Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis. Journal of Translational Medicine, 2017, 15, 82.	1.8	35
243	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	2.0	35
244	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. OncoImmunology, 2017, 6, e1283462.	2.1	34
245	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European Journal of Cancer, 2018, 97, 7-15.	1.3	34
246	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology, 2016, 34, 9500-9500.	0.8	34
247	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology, 2019, 37, 9503-9503.	0.8	34
248	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
249	Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. Critical Reviews in Oncology/Hematology, 2013, 85, 149-161.	2.0	33
250	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
251	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. Journal of Clinical Oncology, 2016, 34, 6-6.	0.8	33
252	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	0.8	33

#	Article	IF	Citations
253	An Assessment of Factors Related to Tumor Thickness and Delay in Diagnosis of Melanoma in Southern Italy. Preventive Medicine, 2002, 35, 271-277.	1.6	32
254	NF-Î°B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. Journal of Translational Medicine, 2012, 10, 252.	1.8	32
255	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. Journal of Translational Medicine, 2014, 12, 291.	1.8	32
256	Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research, 2017, 23, 5238-5245.	3.2	32
257	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	2.0	32
258	Genomic Features of Exceptional Response in Vemurafenib Â± Cobimetinibâ€“treated Patients with BRAFV600-mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	3.2	32
259	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
260	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.. Journal of Clinical Oncology, 2012, 30, 8511-8511.	0.8	32
261	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. Journal of Clinical Oncology, 2014, 32, LBA9008-LBA9008.	0.8	32
262	Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. Journal of Clinical Oncology, 2017, 35, 9519-9519.	0.8	32
263	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine, 2013, 11, 202.	1.8	31
264	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
265	The antiâ€“PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600â€“mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. Journal of Clinical Oncology, 2019, 37, 9531-9531.	0.8	31
266	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	3.2	31
267	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Letters, 2009, 274, 331-336.	3.2	30
268	Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. Journal of Translational Medicine, 2012, 10, 131.	1.8	30
269	Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer, 2014, 120, 1617-1619.	2.0	30
270	Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 751-758.	1.8	30

#	Article	IF	Citations
271	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2021, 39, 9507-9507.	0.8	30
272	Sun exposure and melanoma prognostic factors. Oncology Letters, 2016, 11, 2706-2714.	0.8	29
273	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Annals of Oncology, 2017, 28, v429-v430.	0.6	29
274	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine, 2020, 18, 121.	1.8	29
275	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget, 2015, 6, 24823-24841.	0.8	29
276	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. European Journal of Cancer, 2007, 43, 137-143.	1.3	28
277	What have we learned from cancer immunotherapy in the last 3Âyears?. Journal of Translational Medicine, 2014, 12, 141.	1.8	28
278	The immuneâ€related role of BRAF in melanoma. Molecular Oncology, 2015, 9, 93-104.	2.1	28
279	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
280	Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Research, 2004, 24, 4255-8.	0.5	28
281	Issues affecting molecular staging in the management of patients with melanoma. Journal of Cellular and Molecular Medicine, 2007, 11, 1052-1068.	1.6	27
282	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	2.2	27
283	New paradigm for stage III melanoma: from surgery to adjuvant treatment. Journal of Translational Medicine, 2019, 17, 266.	1.8	27
284	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	1.3	27
285	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 2021, 124, 574-580.	2.9	27
286	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Frontiers in Oncology, 2015, 5, 152.	1.3	26
287	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncology, The, 2016, 17, 1037-1039.	5.1	26
288	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. Annals of Oncology, 2017, 28, v428.	0.6	26

#	Article	IF	Citations
289	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. Cancers, 2020, 12, 2914.	1.7	26
290	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
291	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	1.3	26
292	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	3.4	26
293	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. Journal of Clinical Oncology, 2020, 38, 10005-10005.	0.8	26
294	Do BRAF inhibitors select for populations with different disease progression kinetics?. Journal of Translational Medicine, 2013, 11, 61.	1.8	25
295	Integrating first-line treatment options into clinical practice. Melanoma Research, 2015, 25, 461-469.	0.6	25
296	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	1.8	25
297	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutationâ€“positive melanoma receiving adjuvant vemurafenib. Annals of Oncology, 2020, 31, 153-159.	0.6	25
298	Cd40 Activation as Potential Tool in Malignant Neoplasms. Tumori, 2002, 88, 361-366.	0.6	24
299	Soluble interleukin-2 receptor in stage Iâ€“III melanoma. Cytokine, 2006, 33, 150-155.	1.4	24
300	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	24
301	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	1.8	24
302	Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Management, 2017, 4, 175-178.	0.1	24
303	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. BMC Cancer, 2019, 19, 772.	1.1	24
304	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. Journal of Translational Medicine, 2019, 17, 289.	1.8	24
305	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
306	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 4544.	1.8	24

#	Article	IF	Citations
307	A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.. Journal of Clinical Oncology, 2017, 35, 9518-9518.	0.8	24
308	Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF^{V600} mutationâ€“positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.. Journal of Clinical Oncology, 2018, 36, 9522-9522.	0.8	24
309	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instabilityâ€“high (MSI-H) tumors.. Journal of Clinical Oncology, 2019, 37, 670-670.	0.8	24
310	Immunomodulatory pathways regulate expression of a spliced <scp>FKBP</scp>51 isoform in lymphocytes of melanoma patients. Pigment Cell and Melanoma Research, 2015, 28, 442-452.	1.5	23
311	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology, 2016, 39, 30-38.	2.4	23
312	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. Clinical Cancer Research, 2020, 26, 5102-5112.	3.2	23
313	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. , 2021, 9, e001694.		23
314	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9504-9504.	0.8	23
315	Phenotype characterization of human melanoma cells resistant to dabrafenib. Oncology Reports, 2017, 38, 2741-2751.	1.2	22
316	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2018, 97, 59-61.	1.3	22
317	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers, 2019, 11, 1425.	1.7	22
318	LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno) Tj ETQq0 0 0 rgBT /Overlock 1	0.6	22
319	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 2022, 33, 968-980.	0.6	22
320	Cisplatin, dacarbazine, and fotemustine plus interferon Î± in patients with advanced malignant melanoma. Cancer, 2000, 89, 2630-2636.	2.0	21
321	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Î± in advanced malignant melanoma. Journal of Translational Medicine, 2013, 11, 38.	1.8	21
322	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Annals of Oncology, 2016, 27, 1947.	0.6	21
323	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
324	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer, 2011, 11, 451.	1.1	20

#	Article	IF	Citations
325	Expression of the Anti-Apoptotic Protein BAG3 in Human Melanomas. Journal of Investigative Dermatology, 2012, 132, 252-254.	0.3	20
326	Cosmic radiation and cancer: is there a link?. Future Oncology, 2015, 11, 1123-1135.	1.1	20
327	Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 271-274.	2.0	20
328	Impact of depth of response on survival in patients treated with cobimetinibâ€‰Â±â€‰vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. British Journal of Cancer, 2019, 121, 522-528.	2.9	20
329	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. Journal of Translational Medicine, 2019, 17, 376.	1.8	20
330	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology, 2020, 16, 2165-2175.	1.1	20
331	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 2021, 13, 475.	1.7	20
332	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. International Journal of Molecular Sciences, 2021, 22, 1801.	1.8	20
333	Epigenetic Regulation in Melanoma: Facts and Hopes. Cells, 2021, 10, 2048.	1.8	20
334	Management of cutaneous melanoma: radiologists challenging and risk assessment. Radiologia Medica, 2022, 127, 899-911.	4.7	20
335	Sentinel lymph node biopsy in patients with cutaneous melanoma: outcome after 3-year follow-up. European Journal of Surgical Oncology, 2004, 30, 440-443.	0.5	19
336	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer, 2006, 6, 266.	1.1	19
337	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncology Reports, 2011, 25, 1495-502.	1.2	19
338	Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology, 2016, 27, vi379.	0.6	19
339	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutationâ€“positive melanoma. British Journal of Cancer, 2018, 118, 777-784.	2.9	19
340	Adverse events 2.0â€”Let us get SERIOs. European Journal of Cancer, 2019, 112, 29-31.	1.3	19
341	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Management, 2019, 6, MMT30.	0.1	19
342	Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. World Journal of Surgical Oncology, 2013, 11, 36.	0.8	18

#	Article	IF	Citations
343	Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunology, Immunotherapy, 2016, 65, 1395-1400.	2.0	18
344	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
345	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	1.8	18
346	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. Journal of Clinical Oncology, 2015, 33, 3012-3012.	0.8	18
347	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. Journal of Clinical Oncology, 2019, 37, 2512-2512.	0.8	18
348	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clinical Cancer Research, 2022, 28, 3002-3010.	3.2	18
349	Prognostic and predictive value of Î²-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2022, 165, 97-112.	1.3	18
350	Tumor biobanks in translational medicine. Journal of Translational Medicine, 2012, 10, 204.	1.8	17
351	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy, 2014, 26, 193-201.	0.7	17
352	SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 331-338.	1.4	17
353	Who Benefits Most From Adjuvant Interferon Treatment for Melanoma?. American Journal of Therapeutics, 2015, 22, 54-60.	0.5	17
354	Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 180.	3.5	17
355	Neoadjuvant therapy in melanoma: the next step?. Lancet Oncology, The, 2018, 19, 151-153.	5.1	17
356	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. Journal of Clinical Oncology, 2021, 39, 9516-9516.	0.8	17
357	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. Journal of Clinical Oncology, 2017, 35, 9524-9524.	0.8	17
358	The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. Journal of Clinical Medicine, 2021, 10, 4935.	1.0	17
359	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers, 2022, 14, 377.	1.7	17
360	Immunological Phenotype Analysis of Patients with Fanconiâ€™s Anaemia and Their Family Members. Acta Haematologica, 1998, 100, 39-43.	0.7	16

#	Article	IF	Citations
361	Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy, 2016, 16, 433-441.	1.4	16
362	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advancedNRAS- orBRAF-mutated melanoma. Oncotarget, 2019, 10, 1850-1859.	0.8	16
363	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma. Cancer Research, 2019, 79, CT037-CT037.	0.4	16
364	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600â€“mutant melanoma.. Journal of Clinical Oncology, 2019, 37, 9512-9512.	0.8	16
365	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. European Journal of Dermatology, 2018, 28, 775-783.	0.3	16
366	Update on PEG-interferon Î±-2b as adjuvant therapy in melanoma. Anticancer Research, 2012, 32, 3901-9.	0.5	16
367	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	1.8	15
368	Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). Annals of Oncology, 2016, 27, vi379.	0.6	15
369	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
370	Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. Medicina (Lithuania), 2020, 56, 377.	0.8	15
371	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. International Journal of Molecular Sciences, 2020, 21, 1930.	1.8	15
372	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15
373	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. Journal of Clinical Oncology, 2018, 36, e21588-e21588.	0.8	15
374	Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. Journal of Clinical Oncology, 2019, 37, 487-487.	0.8	15
375	MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. Journal of Human Genetics, 2010, 55, 518-524.	1.1	14
376	EGFR mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	1.5	14
377	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021, 31, 181-185.	0.6	14
378	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	1.8	14

#	Article	IF	Citations
379	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	1.3	14
380	Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?. Current Opinion in Oncology, 2021, 33, 133-138.	1.1	14
381	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10012-10012.	0.8	14
382	CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. New England Journal of Medicine, 2022, 386, 1668-1669.	13.9	14
383	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. Journal of Clinical Oncology, 2007, 25, e20-e21.	0.8	13
384	The role of spectrophotometry in the diagnosis of melanoma. BMC Dermatology, 2010, 10, 5.	2.1	13
385	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. Journal of Investigative Dermatology, 2016, 136, 1917-1920.	0.3	13
386	Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist, 2017, 22, 951-962.	1.9	13
387	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Melanoma Research, 2018, 28, 333-340.	0.6	13
388	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	1.3	13
389	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
390	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. Journal of Translational Medicine, 2020, 18, 489.	1.8	13
391	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
392	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opinion on Emerging Drugs, 2021, 26, 79-92.	1.0	13
393	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. Journal of Clinical Oncology, 2012, 30, 8573-8573.	0.8	13
394	Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.. Journal of Clinical Oncology, 2019, 37, 2517-2517.	0.8	13
395	Late onset Blueberry Muffin Syndrome following congenital rubella. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 204-205.	1.3	12
396	Prognostic Value of CD40 in Adult Soft Tissue Sarcomas. Clinical Cancer Research, 2004, 10, 2824-2831.	3.2	12

#	Article	IF	Citations
397	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunology, Immunotherapy, 2005, 54, 44-50.	2.0	12
398	The Role of Optical Radiations in Skin Cancer. ISRN Dermatology, 2013, 2013, 1-8.	1.9	12
399	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab. Journal of Translational Medicine, 2014, 12, P11.	1.8	12
400	Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. , 2015, 3, .		12
401	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 2017, 27, 243-250.	0.6	12
402	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1143-1151.	2.0	12
403	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS Journal, 2017, 11, 91-100.	0.1	12
404	Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology, 2018, 29, viii413.	0.6	12
405	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. International Journal of Oncology, 2018, 53, 1149-1159.	1.4	12
406	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock		12
407	Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis. Journal of Translational Medicine, 2021, 19, 132.	1.8	12
408	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 2021, 149, 37-48.	1.3	12
409	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12
410	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
411	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. Journal of Clinical Medicine, 2021, 10, 136.	1.0	12
412	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Current Medicinal Chemistry, 2020, 27, 2792-2813.	1.2	12
413	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€“positive melanoma. Annals of Oncology, 2022, 33, 544-555.	0.6	12
414	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Journal of Translational Medicine, 2022, 20, 159.	1.8	12

#	Article	IF	Citations
415	Mutation analysis of candidate genes in melanoma-prone families. Melanoma Research, 2003, 13, 571-579.	0.6	11
416	Lean oncology: a new model for oncologists. Journal of Translational Medicine, 2012, 10, 74.	1.8	11
417	Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies. Cancer Letters, 2015, 357, 286-296.	3.2	11
418	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. American Journal of Therapeutics, 2015, 22, 44-53.	0.5	11
419	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget, 2018, 9, 12408-12417.	0.8	11
420	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicines, 2022, 10, 150.	1.4	11
421	Adjuvant treatment of malignant melanoma: Where are we?. Critical Reviews in Oncology/Hematology, 2006, 57, 45-52.	2.0	10
422	Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. Annals of Oncology, 2008, 19, 2092-2093.	0.6	10
423	Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, The, 2015, 16, 15-17.	5.1	10
424	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opinion on Biological Therapy, 2016, 16, 1479-1489.	1.4	10
425	Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Annals of Oncology, 2016, 27, vi379.	0.6	10
426	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	1.3	10
427	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Journal of Clinical Medicine, 2020, 9, 2430.	1.0	10
428	No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. OncoImmunology, 2020, 9, 1826132.	2.1	10
429	How we treat locoregional melanoma. ESMO Open, 2021, 6, 100136.	2.0	10
430	Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study.. Journal of Clinical Oncology, 2016, 34, 9530-9530.	0.8	10
431	ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.. Journal of Clinical Oncology, 2019, 37, TPS9599-TPS9599.	0.8	10
432	Intermediate dose recombinant interferon-? as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer, 2000, 89, 1490-1494.	2.0	9

#	Article	IF	Citations
433	Sentinel lymph node biopsy does not change melanoma-specific survival among patients with breslow thickness greater than four millimeters. Annals of Surgical Oncology, 2004, 11, 198S-202S.	0.7	9
434	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
435	Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. , 2015, 3, P186.		9
436	Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. Future Oncology, 2015, 11, 1429-1435.	1.1	9
437	Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi. Oncology Letters, 2016, 12, 1349-1354.	0.8	9
438	Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. Annals of Oncology, 2018, 29, viii725.	0.6	9
439	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84.	0.2	9
440	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. Journal of Clinical Medicine, 2019, 8, 1577.	1.0	9
441	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutationâ€“positive metastatic melanoma treated with vemurafenib Â± cobimetinib. European Journal of Cancer, 2019, 116, 45-55.	1.3	9
442	Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. OncoImmunology, 2020, 9, 1710389.	2.1	9
443	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9070-9070.	0.8	9
444	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. Journal of Clinical Oncology, 2017, 35, e20504-e20504.	0.8	9
445	A Metabolomics-Based Screening Proposal for Colorectal Cancer. Metabolites, 2022, 12, 110.	1.3	9
446	STARBOARD: encorafenibÂ+ÂbinimetinibÂ+ pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncology, 2022, 18, 2041-2051.	1.1	9
447	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
448	Adjuvant therapy of cutaneous melanoma. Lancet, The, 1999, 353, 328.	6.3	8
449	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatology, 2009, 9, 7.	2.1	8
450	MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 1364-1365.	13.9	8

#	Article	IF	Citations
451	Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. Journal of Investigative Dermatology, 2013, 133, 1685-1687.	0.3	8
452	Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report. BMC Dermatology, 2014, 14, 15.	2.1	8
453	3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. European Journal of Cancer, 2015, 51, S667-S668.	1.3	8
454	MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies. Annals of Oncology, 2018, 29, x4.	0.6	8
455	Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Annals of Oncology, 2018, 29, viii737.	0.6	8
456	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. Annals of Oncology, 2020, 31, S734-S735.	0.6	8
457	The clinical and translational research activities at the INT â€“ IRCCS â€œFondazione Pascaleâ€•cancer center (Naples, Italy) during the COVID-19 pandemic. Infectious Agents and Cancer, 2020, 15, 69.	1.2	8
458	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenibâ€‰Â±â€‰cobimetinib: a pooled analysis of four clinical trials. Journal of Translational Medicine, 2020, 18, 294.	1.8	8
459	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. International Journal of Cancer, 2021, 149, 1926-1934.	2.3	8
460	Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i. Cancer Research, 2018, 78, CT182-CT182.	0.4	8
461	The antiâ€“PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600â€“mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. Journal of Clinical Oncology, 2020, 38, 10028-10028.	0.8	8
462	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European Journal of Cancer, 2021, 158, 225-233.	1.3	8
463	Sentinel Lymph Node Biopsy to Stage Patients with Cutaneous Melanoma at the National Cancer Institute of Naples. Results from 240 Sentinel Node Biopsies. Tumori, 2002, 88, S12-S13.	0.6	7
464	A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: Potential applications in autoimmunity and cancer. Human Immunology, 2014, 75, 730-739.	1.2	7
465	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Management, 2015, 2, 209-215.	0.1	7
466	Electrochemotherapy in melanoma patients: a single institution experience. Melanoma Management, 2015, 2, 127-132.	0.1	7
467	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 41-50.	0.1	7
468	melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Annals of Oncology, 2016, 27, vi574.	0.6	7

#	Article	IF	Citations
469	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. Annals of Oncology, 2018, 29, viii456.	0.6	7
470	The Ratio of GrzB+ â˜' FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers, 2021, 13, 2325.	1.7	7
471	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 2021, 13, 2466.	1.7	7
472	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	1.3	7
473	PIVOT-12: aÂphase IIIÂstudy of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology, 2022, 18, 903-913.	1.1	7
474	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	1.1	7
475	Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research. , 2022, 10, e004397.		7
476	The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. Annals of Oncology, 2010, 21, 1379-1380.	0.6	6
477	Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies. Tumori, 2013, 99, e302-e305.	0.6	6
478	Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Annals of Oncology, 2015, 26, vi74.	0.6	6
479	Vemurafenib inBRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	1.1	6
480	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). Annals of Oncology, 2017, 28, v632-v633.	0.6	6
481	Association of programmed death ligandâ€1 (PDâ€L1) expression with treatment outcomes in patients with <scp>BRAF</scp> mutationâ€positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell and Melanoma Research, 2018, 31, 516-522.	1.5	6
482	Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs in Context, 2019, 8, 1-6.	1.0	6
483	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. Expert Opinion on Therapeutic Targets, 2019, 23, 53-68.	1.5	6
484	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	1.8	6
485	1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047. Annals of Oncology, 2021, 32, S867-S868.	0.6	6
486	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. Journal of Clinical Oncology, 2017, 35, 9512-9512.	0.8	6

#	Article	IF	Citations
487	Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAF^{V600}-mutated metastatic melanoma (mM).. Journal of Clinical Oncology, 2017, 35, 9556-9556.	0.8	6
488	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. Journal of Clinical Oncology, 2019, 37, 9584-9584.	0.8	6
489	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Frontiers in Immunology, 2022, 13, 811131.	2.2	6
490	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	1.7	6
491	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
492	Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer, 2005, 103, 653-653.	2.0	5
493	Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals of Oncology, 2017, 28, v229-v230.	0.6	5
494	Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067). Annals of Oncology, 2017, 28, v432-v433.	0.6	5
495	Selecting immuno-oncologyâ€“based drug combinations â€“ what should we be considering?. Expert Review of Clinical Pharmacology, 2018, 11, 971-985.	1.3	5
496	Health-related quality of life in patients with fully resected BRAFV600 mutationâ€“positive melanoma receiving adjuvant vemurafenib. European Journal of Cancer, 2019, 123, 155-161.	1.3	5
497	Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: realâ€world data from a large Italian database. British Journal of Dermatology, 2020, 183, 172-174.	1.4	5
498	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€“7th, 2019,) Tj ETQq0 0 0 rgBT /Overlock	1.8	5
499	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. Journal of Translational Medicine, 2021, 19, 70.	1.8	5
500	Ipilimumab and Stereotactic Radiosurgery with CyberKnifeÂ® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers, 2021, 13, 1857.	1.7	5
501	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 2021, 13, 4164.	1.7	5
502	Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).. Journal of Clinical Oncology, 2016, 34, 9528-9528.	0.8	5
503	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600â€“mutant melanoma.. Journal of Clinical Oncology, 2017, 35, 9526-9526.	0.8	5
504	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. Journal of Clinical Oncology, 2017, 35, 9543-9543.	0.8	5

#	Article	IF	Citations
505	SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.. Journal of Clinical Oncology, 2017, 35, TPS9598-TPS9598.	0.8	5
506	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology, 2019, 37, TPS9596-TPS9596.	0.8	5
507	Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort. Annals of Oncology, 2022, 33, 445-447.	0.6	5
508	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. International Journal of Oncology, 2003, 22, 1209-15.	1.4	5
509	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Scientific Reports, 2022, 12, 5448.	1.6	5
510	Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. Annals of Oncology, 2000, 11, 1504.	0.6	4
511	The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma. Annals of Oncology, 2012, 23, ix367-ix368.	0.6	4
512	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. Expert Review of Dermatology, 2013, 8, 479-487.	0.3	4
513	Melanoma: the role of surgery in the era of new therapies. Journal of Translational Medicine, 2014, 12, 195.	1.8	4
514	3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). European Journal of Cancer, 2015, 51, S633.	1.3	4
515	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology, 2018, 2, 1-18.	1.5	4
516	The great debate at â€œImmunotherapy Bridge 2018â€, Naples, November 29th, 2018. , 2019, 7, 221.		4
517	Nivolumab for the treatment of small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 5-13.	1.0	4
518	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. Cell Communication and Signaling, 2020, 18, 150.	2.7	4
519	Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nature Reviews Clinical Oncology, 2020, 17, 198-199.	12.5	4
520	Perspectives on COVID-19 and cancer immunotherapy: a review series. , 2021, 9, e002489.		4
521	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2021, 39, 2565-2565.	0.8	4
522	Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytesâ€™ iTNF-Î± Expression. Biology, 2021, 10, 735.	1.3	4

#	Article	IF	Citations
523	A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, TPS9106-TPS9106.	0.8	4
524	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11.	1.3	4
525	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, .	1.8	4
526	Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposiâ€™s sarcoma. Annals of Oncology, 2000, 11, 635-636.	0.6	3
527	Efficacy, Safety, and Quality of Life (Qol) Data from the Eortc 18071 Phase III Trial of Ipilimumab (Ipi) Versus Placebo After Complete Resection of Stage III Melanoma. Annals of Oncology, 2014, 25, iv375.	0.6	3
528	Epidemiological and genetic factors underlying melanoma development in Italy. Melanoma Management, 2015, 2, 149-163.	0.1	3
529	Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. Melanoma Management, 2015, 2, 9-14.	0.1	3
530	Editorial: Combination Strategies in the Treatment of Melanoma. Frontiers in Oncology, 2016, 6, 67.	1.3	3
531	The Great Debate at â€œMelanoma Bridgeâ€, Napoli, December 2nd, 2017. Journal of Translational Medicine, 2018, 16, 101.	1.8	3
532	Elevated Levels of BRAF^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3
533	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). Annals of Oncology, 2018, 29, viii465-viii466.	0.6	3
534	Quality assurance in melanoma care: The EU-MELACARE study. European Journal of Surgical Oncology, 2018, 44, 1773-1778.	0.5	3
535	Enzyme activity of circulating CD73 in human serum. Methods in Enzymology, 2019, 629, 257-267.	0.4	3
536	The Great Debate at â€˜Immunotherapy Bridgeâ€™, Naples, December 5, 2019. , 2020, 8, e000921.		3
537	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. Future Oncology, 2020, 16, 1091-1100.	1.1	3
538	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq0 0 0 rgBT /Over	1.8	3
539	Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. Journal of Translational Medicine, 2021, 19, 93.	1.8	3
540	Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19. Annals of Oncology, 2021, 32, 674-676.	0.6	3

#	Article	IF	Citations
541	Open-label, multicenter safety study of vemurafenib in patients with BRAF^{V600} mutationâ€“positive metastatic melanoma.. Journal of Clinical Oncology, 2013, 31, 9046-9046.	0.8	3
542	Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).. Journal of Clinical Oncology, 2014, 32, 9034-9034.	0.8	3
543	NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology, 2014, 32, TPS9102-TPS9102.	0.8	3
544	Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).. Journal of Clinical Oncology, 2015, 33, 9021-9021.	0.8	3
545	Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).. Journal of Clinical Oncology, 2016, 34, 9532-9532.	0.8	3
546	Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) Â± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.. Journal of Clinical Oncology, 2016, 34, 9536-9536.	0.8	3
547	Adverse events of special interest in the phase 3 COLUMBUS study.. Journal of Clinical Oncology, 2018, 36, 9567-9567.	0.8	3
548	CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. Journal of Clinical Oncology, 2019, 37, TPS9601-TPS9601.	0.8	3
549	Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.. Journal of Clinical Oncology, 2019, 37, 31-31.	0.8	3
550	Cost of illness of cutaneous squamous cell carcinoma (CSCC). Global & Regional Health Technology Assessment, 2020, 7, 148-153.	0.2	3
551	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 702.	1.7	3
552	Health-related quality of life in patients treated with pembrolizumab for microsatellite instabilityâ€“high/mismatch repairâ€“deficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer, 2022, 169, 188-197.	1.3	3
553	Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridgeâ€”December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, .	1.8	3
554	Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. , 2022, 10, e004742.		3
555	Low doses interferon-Î± in the treatment of high-risk cutaneous melanoma. Annals of Oncology, 2000, 11, 487-490.	0.6	2
556	The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. , 2013, 1, .		2
557	Combination therapies in advanced melanoma. Melanoma Management, 2014, 1, 47-56.	0.1	2
558	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. Journal of Translational Medicine, 2015, 13, O8.	1.8	2

#	Article	IF	Citations
559	Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs, 2015, 26, 464-468.	0.7	2
560	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. Annals of Oncology, 2017, 28, v442.	0.6	2
561	How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. Annals of Oncology, 2018, 29, 2157-2160.	0.6	2
562	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	1.8	2
563	ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. Annals of Oncology, 2019, 30, v560-v561.	0.6	2
564	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. Methods in Enzymology, 2020, 635, 21-31.	0.4	2
565	The Great Debate at â€œMelanoma Bridgeâ€, Naples, December 7th, 2019. Journal of Translational Medicine, 2020, 18, 171.	1.8	2
566	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e343-e344.	5.1	2
567	Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma. , 2016, , .		2
568	Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436).. Journal of Clinical Oncology, 2012, 30, 8518-8518.	0.8	2
569	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. Journal of Clinical Oncology, 2016, 34, 9526-9526.	0.8	2
570	Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study.. Journal of Clinical Oncology, 2016, 34, 9533-9533.	0.8	2
571	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600â€“mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. Journal of Clinical Oncology, 2019, 37, 9515-9515.	0.8	2
572	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600â€“mutant melanoma.. Journal of Clinical Oncology, 2020, 38, 10034-10034.	0.8	2
573	Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori, 2013, 99, 302e-5e.	0.6	2
574	What is changing in the adjuvant treatment of melanoma?. Oncotarget, 2017, 8, 110735-110736.	0.8	2
575	The Future of Melanoma Therapy is the Combination Approach. Journal of Molecular Biomarkers & Diagnosis, 2011, 02, .	0.4	2
576	Abstract 3677: Pattern and distribution of BRAF/NRAS and P16CDKN2Amutations among primary an secondary lesions in melanoma patients. , 2012, , .		2

#	Article	IF	Citations
577	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.3	2
578	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	1.3	2
579	Imaging Assessment of Interval Metastasis from Melanoma. Journal of Personalized Medicine, 2022, 12, 1033.	1.1	2
580	PP 65 Are GSK2118436 and GSK1120212 effective in melanoma cell lines harboring V600BRAF mutations different from the common V600EBRAF variant?. European Journal of Cancer, 2011, 47, S11.	1.3	1
581	Melanoma: From Research to Treatment. Journal of Skin Cancer, 2011, 2011, 1-2.	0.5	1
582	Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer. , 2014, 2, 15.		1
583	Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000230.	0.2	1
584	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. Immunotherapy, 2016, 8, 681-686.	1.0	1
585	EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg. Radiotherapy and Oncology, 2016, 119, S649-S650.	0.3	1
586	Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) Â± cobimetinib (COBI): A pooled analysis. Annals of Oncology, 2016, 27, vi391.	0.6	1
587	PO-0741: Ipilimumab and stereotactic radiosurgery with cyberknife in melanoma brain metastases. Radiotherapy and Oncology, 2017, 123, S389-S390.	0.3	1
588	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. , 2018, , 565-578.		1
589	Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). Annals of Oncology, 2018, 29, viii203.	0.6	1
590	Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad hoc expanded access program (EAP). Annals of Oncology, 2018, 29, x29.	0.6	1
591	Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP). Annals of Oncology, 2018, 29, viii460-viii461.	0.6	1
592	Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma. , 2018, , 85-96.		1
593	Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models. Annals of Oncology, 2019, 30, v531.	0.6	1
594	Reply to E. HindiÃ©. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1

#	Article	IF	Citations
595	The â€œGreat Debateâ€•at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine, 2021, 19, 142.	1.8	1
596	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2ndâ€“3rd,) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	1
597	Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma. Frontiers in Oncology, 2021, 11, 728113.	1.3	1
598	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
599	Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP). Annals of Oncology, 2012, 23, ix369-ix370.	0.6	1
600	Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNÎ± combination in BRAF mutant melanoma. , 2016, , .		1
601	Immunoscore as new possible approach for the classification of melanoma.. Journal of Clinical Oncology, 2014, 32, e20020-e20020.	0.8	1
602	Expansion of a lymphocyte subset expressing a spliced FKBP51 isoform in melanoma patients.. Journal of Clinical Oncology, 2015, 33, e20070-e20070.	0.8	1
603	Mobile hospital rooms to fight melanoma. Melanoma Research, 2001, 11, 83-84.	0.6	1
604	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. Journal of Clinical Oncology, 2019, 37, TPS145-TPS145.	0.8	1
605	Detection of tyrosinase mRNA in tumor tissue microdissections from classic Kaposiâ€™s sarcoma. Annals of Oncology, 2001, 12, 1765-1766.	0.6	0
606	9322 POSTER Immunological and Biological Changes and Their Correlation With Clinical Response and Survival During Ipilimumab in Metastatic Melanoma Compassionate Use Program. European Journal of Cancer, 2011, 47, S658-S659.	1.3	0
607	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
608	Multiple Primary Melanomas from Same Patients Present Discrepant Somatic Alterations in Main Candidate Genes. Annals of Oncology, 2012, 23, ix364.	0.6	0
609	Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program. Annals of Oncology, 2012, 23, ix373-ix374.	0.6	0
610	Ipilimuamb Treatment after Electrochemotherapy Could be An Effective Sequential Combination Approach. Annals of Oncology, 2012, 23, ix375.	0.6	0
611	An Open-Label, Multicentre Safety Study of Vemurafenib in Patients with Metastatic Melanoma. Annals of Oncology, 2012, 23, ix366.	0.6	0
612	Advances in immunotherapy for melanoma. Melanoma Management, 2014, 1, 19-24.	0.1	0

#	Article	IF	Citations
613	3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study. European Journal of Cancer, 2015, 51, S681-S682.	1.3	0
614	3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine. European Journal of Cancer, 2015, 51, S683.	1.3	0
615	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. Cancer Drug Discovery and Development, 2015, , 245-258.	0.2	0
616	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
617	Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study. Annals of Oncology, 2016, 27, vi398.	0.6	0
618	EP-1396: Radiosurgery/Stereotacticradiotherapy with Cyberknife and immunotherapy in melanoma brain metastases. Radiotherapy and Oncology, 2016, 119, S651.	0.3	0
619	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€, Napoli, December 5th 2015. , 2016, 4, .		0
620	CD73 activity and outcome of advanced melanoma patients treated with nivolumab. European Journal of Cancer, 2018, 92, S22.	1.3	0
621	ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. Annals of Oncology, 2018, 29, viii466.	0.6	0
622	Systemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer. Annals of Oncology, 2019, 30, v1-v2.	0.6	0
623	Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study. Annals of Oncology, 2019, 30, v561.	0.6	0
624	Immunotherapies and Novel Combinations. , 2019, , 643-653.		0
625	The â€œGreat Debateâ€•at Immunotherapy Bridge 2020, December 3rd, 2020. Journal of Translational Medicine, 2021, 19, 144.	1.8	0
626	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	1.0	0
627	Abstract A79: Expression of argininosuccinate synthetase (ASS) and response to arginine deiminase (ADI) treatment in a series of melanoma cell lines. , 2009, , .		0
628	Marker Utility for Combination Therapy. Methods in Molecular Biology, 2014, 1102, 97-115.	0.4	0
629	BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.. Journal of Clinical Oncology, 2014, 32, TPS9109-TPS9109.	0.8	0
630	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. Journal of Clinical Oncology, 2014, 32, TPS9105-TPS9105.	0.8	0

#	Article	IF	Citations
631	Mutation analysis of mucosal and cutaneous melanomas during progression.. Journal of Clinical Oncology, 2017, 35, e21047-e21047.	0.8	0
632	Abstract 2624: An FKBP5-based immunophenotype for assessment of the immunosuppression status and possible prediction of immunotherapy response in melanoma patients. , 2017, , .		0
633	Mutation frequencies in a gene panel among primary tumors and metastases in patients with melanoma.. Journal of Clinical Oncology, 2018, 36, e21554-e21554.	0.8	0
634	Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. , 2018, , .		0
635	Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations. , 2019, , .		0
636	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. Journal of Clinical Oncology, 2019, 37, 2559-2559.	0.8	0
637	The ACC melanoma pilot project: â€œReal-worldâ€•evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	0.8	0
638	Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM). , 2019, , .		0
639	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
640	Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al. , 2022, 10, e004347.		0
641	The â€œGreat Debateâ€•at Immunotherapy Bridge 2021, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, 179.	1.8	0
642	The â€œGreat Debateâ€•at Melanoma Bridge 2021, December 2ndâ€“4th, 2021. Journal of Translational Medicine, 2022, 20, 200.	1.8	0